Biotech Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea December 12, 2022
Biotech 100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML) December 12, 2022
Biotech Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation December 12, 2022
Biotech Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference December 12, 2022
Biotech CTI BioPharma Presents New Anemia Benefit Data from Pacritinib Program at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition December 11, 2022
Biotech Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid December 11, 2022
Biotech ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EIGR December 10, 2022
Biotech Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma December 10, 2022
Biotech Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting December 10, 2022
Biotech EIGR INVESTOR NEWS: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EIGR December 9, 2022
Search
xbi stock
December 12, 2022
December 12, 2022
December 12, 2022
December 12, 2022
December 11, 2022
December 11, 2022
December 10, 2022
December 10, 2022
December 10, 2022
December 9, 2022
